Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | GCK | P35557 | 12/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171465 | 0.90 | KCNH2 (0.63) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171463 | 0.90 | KCNH2 (0.63) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1445384 | 0.90 | KCNH2 (0.63) | KCNH2GCKMEN1KMT2ASLC6A3 | |
| SCHEMBL1445381 | 0.90 | KCNH2 (0.63) | KCNH2GCKMEN1KMT2ASLC6A3 | |
| SCHEMBL2647926 | 0.89 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171354 | 0.89 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL2650827 | 0.89 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171349 | 0.89 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171353 | 0.89 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171351 | 0.88 | KCNH2 (0.61) | KCNH2GCKMEN1KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KCNH2 716/4885GCK 2/4885MEN1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.